日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tau-targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy.

针对 Tau 蛋白的主动免疫疗法可减缓 tau 蛋白病小鼠模型的病情进展并减轻病理变化。

Brown Christopher M, Brooks Jeanne K, Kelly Louise, Vroom Madeline M, Longo Matthew, Dodart Jean-Cosme, Carare Roxana, Boyd Justin D

Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide.

针对降钙素基因相关肽的活性免疫疗法的临床前表征

Boyd Justin D, Wang Shixia, Lin Hsiao-Wen, Hsieh Yueh-Ting, Sun Yu Shuang, Thibodeaux Brett A, Lu Hanxin, Sahni Jaya, Wiggins Jonathan, Longo Matthew S, Brooks Jeanne K, Vroom Madeline M, Chang Yi-Pin, Liu Zhi, Ding Shuang, Dodart Jean-Cosme

Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA), updates in 2022-2023. Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy

间质液 (ISF) 和脑脊液 (CSF) 清除 (CLIC) 小组——血管专业兴趣领域 (PIA) 的一部分,2022-2023 年更新。脑血管疾病以及随着年龄增长和阿尔茨海默病,大脑和视网膜中β-淀粉样蛋白清除障碍:治疗机遇

Kelly, Louise; Brown, Christopher; Michalik, Daniel; Hawkes, Cheryl A; Aldea, Roxana; Agarwal, Nivedita; Salib, Rami; Alzetani, Aiman; Ethell, Douglas W; Counts, Scott E; de Leon, Mony; Fossati, Silvia; Koronyo-Hamaoui, Maya; Piazza, Fabrizio; Rich, Steven A; Wolters, Frank J; Snyder, Heather; Ismail, Ozama; Elahi, Fanny; Proulx, Steven T; Verma, Ajay; Wunderlich, Hilary; Haack, Mareike; Dodart, Jean Cosme; Mazer, Norman; Carare, Roxana O

VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys

VXX-401是一种新型抗PCSK9疫苗,可降低食蟹猴的低密度脂蛋白胆固醇水平。

Vroom, Madeline M; Lu, Hanxin; Lewis, Maggie; Thibodeaux, Brett A; Brooks, Jeanne K; Longo, Matthew S; Ramos, Martina M; Sahni, Jaya; Wiggins, Jonathan; Boyd, Justin D; Wang, Shixia; Ding, Shuang; Hellerstein, Michael; Ryan, Valorie; Powchik, Peter; Dodart, Jean-Cosme

Active Immunotherapy for the Prevention of Alzheimer's and Parkinson's Disease

主动免疫疗法预防阿尔茨海默病和帕金森病

Vroom, Madeline M; Dodart, Jean-Cosme

Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study

UB-311 在轻度阿尔茨海默病患者中的安全性、耐受性、免疫原性和有效性:一项随机、双盲、安慰剂对照的 2a 期研究

Yu, Hui Jing; Dickson, Samuel P; Wang, Pei-Ning; Chiu, Ming-Jang; Huang, Chin-Chang; Chang, Chiung-Chih; Liu, Hope; Hendrix, Suzanne B; Dodart, Jean-Cosme; Verma, Ajay; Wang, Chang Yi; Cummings, Jeffrey

Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy

更正:新型抗体可检测突触核蛋白病中额外的α-突触核蛋白病理:具有免疫治疗潜力

Nimmo, Jacqui T; Verma, Ajay; Dodart, Jean-Cosme; Wang, Chang Yi; Savistchenko, Jimmy; Melki, Ronald; Carare, Roxana O; Nicoll, James A R

A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine

UB-312(一种UBITh® α-突触核蛋白肽疫苗)的随机首次人体研究

Yu, Hui Jing; Thijssen, Eva; van Brummelen, Emilie; van der Plas, Johan L; Radanovic, Igor; Moerland, Matthijs; Hsieh, Eric; Groeneveld, Geert Jan; Dodart, Jean-Cosme

Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials

淀粉样蛋白β和α-突触核蛋白免疫疗法:从实验研究到临床试验

Nimmo, Jacqui Taryn; Kelly, Louise; Verma, Ajay; Carare, Roxana O; Nicoll, James A R; Dodart, Jean-Cosme